PMA

P030006: PROLIEVE THERMODILATATION SYSTEM

FDA PMA · System, hyperthermia, rf/microwave (benign prostatic hyperplasia),thermotherapy · Medifocus, Inc.

Key facts

PMA number P030006
Trade name PROLIEVE THERMODILATATION SYSTEM
Generic name System, hyperthermia, rf/microwave (benign prostatic hyperplasia),thermotherapy
Applicant Medifocus, Inc.
Owner/operator Medifocus Inc
Product code MEQ
Approval date Feb 19, 2004
Docket number 04M-0116
Notice date Mar 9, 2004
Establishment registration 3009969279
FEI number 3009969279

At a glance

  • 10–99 Supplements
  • Nov 21, 2018 Latest supplement decision
  • No Withdrawn
  • Yes Summary of safety and effectiveness on file
  • 1–9 UDI device identifiers (GUDID)
  • None MAUDE adverse event reports
  • None Recall events

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About PMA approvals

Premarket approval (PMA) is the FDA's most stringent review pathway, required for most Class III devices that support or sustain life or present a potentially unreasonable risk.

Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date:

Browse all PMA approvals